SCHEMBL6069263

SCHEMBL6069263

O=C1NC(=O)C(c2cn(-c3cnc4ccccc4c3)c3ccccc23)=C1c1cn(CCO)c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 7/20 0.61
PRKCB P05771 2/20 0.61
PRKCA P17252 2/20 0.61
PRKCG P05129 1/20 0.61
PRKCZ Q05513 1/20 0.61
PRKCD Q05655 1/20 0.61
KCNH2 Q12809 1/20 0.61
KDR P35968 2/20 0.52
FLT3 P36888 2/20 0.52
CAMK2D Q13557 3/20 0.49
CDK4 P11802 1/20 0.48
PRKACA P17612 1/20 0.48
PRKACG P22612 1/20 0.48
PRKACB P22694 1/20 0.48
CCND1 P24385 1/20 0.48
IDH1 O75874 1/20 0.47
PRKCE Q02156 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774167 0.83 GSK3B (0.81) GSK3BPRKCBPRKCAPRKCGPRKCZ
SCHEMBL1128590 0.82 GSK3B (0.55) GSK3BPRKCBPRKCAKDRFLT3
SCHEMBL1127978 0.81 GSK3B (0.63) GSK3BPRKCBPRKCAPRKCGPRKCZ
SCHEMBL14522482 0.80 GSK3B (0.69) GSK3BPRKCBPRKCAKDRFLT3
SCHEMBL28755542 0.79 GSK3B (0.41) GSK3BPRKCBPRKCAPRKCGPRKCZ
SCHEMBL5754534 0.78 GSK3B (0.76) GSK3BPRKCBPRKCAPRKCGPRKCZ
SCHEMBL5760645 0.77 GSK3B (0.71) GSK3BPRKCBPRKCAPRKCGPRKCZ
SCHEMBL5757856 0.76 GSK3B (1.00) GSK3BPRKCBPRKCAPRKCGPRKCZ
SCHEMBL5754543 0.75 PRKCB (0.65) GSK3BPRKCBPRKCAPRKCGPRKCZ
SCHEMBL5757333 0.75 GSK3B (0.85) GSK3BPRKCBPRKCAPRKCGPRKCZ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6987110-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-17 US disclosed
US-20040059113-A1 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040059113-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK GSK3B 880/4885PRKCB 55/4885PRKCA 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.